newsfilter
← Latest News
Earnings Call Transcripts·

JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - PROKIDNEY CORP

  • Explicit Guidance:

    • Clinical Milestones & Timelines:
      • Anticipated completion of Phase III enrollment in Q1 2025.
      • Anticipated accelerated approval readout (surrogate endpoint: eGFR slope) in Q2 2027.
      • Expected filing of Biologics License Application (BLA) in Q1 2028.
      • Anticipated confirmatory readout (time-to-event composite endpoint) in the second half of 2029.
    • Manufacturing Capacity:
      • Launch capacity: 350 doses/patients annually.
      • Capacity post-launch (~1 year): 500 doses/patients annually via adjacent facility.
      • Long-term target capacity: 3,000 doses/patients within "a few years" via expansion and/or CDMO partnerships.
  • Business-Segment Outlook:

    • Product Launch Strategy: Positioning RuparinCell (now referred to as Rilparencel in some segments) for patients with advanced diabetic kidney disease (Stage 3b/4) on standard of care who continue to progress, targeting a sub-fraction of the 1 million U.S. patients.
    • Pricing Strategy: Aiming for a price point between $400,000 and $500,000 annually, based on comparative analysis with other cell therapies and kidney disease treatments, and value-based savings of up to $200,000 per patient-year by delaying dialysis.
    • Pipeline Expansion: Focus remains solely on advanced diabetic chronic kidney disease for the foreseeable future; no immediate plans to expand into other indications or upstream therapies.
  • Market and Competitive Outlook:

    • Treatment Gap: Identifies residual risk in current standard of care (ACEi, ARBs, SGLT2i, MRAs, GLP-1s), where patients still face kidney/cardiovascular events despite therapy.
    • Demand Trends: Strong recruitment demand observed in Q2/Q3 2024, leading to a strategic decision to extend enrollment to Q1 2025 to ensure all eligible patients are included, impacting the BLA timeline.
    • Patient Commercials: Positioning as a one-to-two-time therapy (vs. daily chronic meds) for a population averaging 8–12 daily medications, aiming to reduce patient burden and caregiver costs.
  • Macro / Industry Outlook:

    • Global Pricing Dynamics: Acknowledges dialysis costs are highest in the U.S. but notes some European countries pay more, while others pay less; implies significant payer value globally.
    • Regulatory Path: Leveraging FDA RMAT designation and accelerated approval pathway based on surrogate eGFR endpoints to gain early market access.
  • Strategic Initiatives:

    • Manufacturing Scale-Up: Construction of an adjacent manufacturing facility completed; tech transfer and validation to follow, targeting 500 annual capacity ~1 year post-launch.
    • Partnership/Financing: Plans to seek external capital (dilutive, partnership, or debt) to fund significant scaling required to meet global demand beyond the current 3,000-dose capacity plan.
    • Data Disclosure: Will share top-line efficacy and safety in Q2 2027; detailed secondary endpoint data (confirmatory events) reserved for ASN Kidney Week 2027 to preserve regulatory "alpha."
  • Risks and Headwinds to Outlook:

    • Timeline Risks: Manufacturing process validation and site inspection readiness delays (due to extended enrollment) have pushed the BLA submission from a potential early 2028 date to Q1 2028.
    • Safety Risks: Specific monitoring required for biopsy-related bleeding, local hematomas, and infection, alongside general comorbidities of the patient population.
    • Event Rate Uncertainty: Confirmatory study timing (H2 2029) depends on event rates (currently modeled at 10–12 per 100 patient-years); higher event rates could accelerate confirmatory data availability.
    • Supply Constraints: Current capacity (350–500 doses) is significantly lower than the addressable market, requiring rapid capital deployment to scale.
  • Management Tone on the Future:

    • Confidence: High confidence in the eGFR slope data translating to clinical event benefits in the confirmatory readout due to the dominance of eGFR-related events in current observations.
    • Conservatism: Emphasizes conservative assumptions in study power (1.5 mL/min/year treatment effect vs. 4.5 mL/min observed in Phase II) and sham group decline rates (3.0 mL/min vs. 5–6 mL/min observed in Phase II untreated).
    • Focus: Strong, singular focus on the current pivotal trial and launch, avoiding distractions to ensure successful execution.
Company
PROKIDNEY CORP
Keywords
PROKIDNEY CORP